Articles tagged with Pancreatic Cancer
A new study led by the University of Michigan Rogel Cancer Center found that patients with three specific variants face no extra risk of dying from their cancer. The researchers used data from the Surveillance, Epidemiology and End Results programs in Georgia and California, looking at a total of about 78,000 patients with breast, colo...
Researchers found that detectable mutant KRAS circulating tumor DNA (ctDNA) indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma. The study suggests that ctDNA assays should be performed prior to treatment to have the highest yield.
Scientists have discovered a potential new treatment strategy for pancreatic cancer by identifying the molecule Neuropeptide Y (NPY) as a key driver of its spread. Blocking NPY's function has been shown to reduce cancer cell movement and metastatic outgrowth, potentially limiting disease progression.
A new type of RAS inhibitor, daraxonrasib (RMC-6236), has shown significant promise when combined with immunotherapy in preclinical models of pancreatic cancer. The study found that the treatment not only inhibited tumor growth but also reshaped the tumor microenvironment to make it more receptive to immunotherapy.
The study found that Black patients have a higher prevalence of PD-L1 overexpression, TP53 mutations, and KRASG12R mutations compared to White patients. This could affect how their cancer progresses and responds to treatment.
Excessive alcohol consumption causes severe digestive problems, including liver damage, stomach disorders, and increased cancer risk. Chronic alcohol use can lead to conditions like cirrhosis, pancreatitis, and colorectal cancer.
Researchers found that pancreatic cancer cells gain a survival edge by carrying copies of critical cancer genes on circular pieces of DNA outside chromosomes. The discovery highlights the importance of targeting extrachromosomal DNA in treating the disease.
Breast cancer death rates are predicted to increase in EU patients aged 80 years and older, while falling in all other age groups. This is attributed to a lack of regular screening and access to modern treatments.
A new study suggests that chronic stress and an unhealthy diet may work together to fuel the early development of pancreatic cancer. Researchers found that both stress-related neurotransmitters and obesity-related hormones activate a protein called CREB, which is linked to cancer cell growth.
Researchers developed a nanoparticle that delivers an mRNA vaccine targeting a KRAS antigen, boosting the immune response against pancreatic cancer. Experiments in mice showed inhibited and prevented tumor growth, as well as long-term protection against recurrence.
Researchers identified co-occurring genetic alterations in colorectal and pancreatic cancers that contribute to resistance to KRAS G12C inhibitors. These mutations can lead to poor prognosis and chemotherapy resistance.
Researchers at Trinity College Dublin have discovered a biomarker panel that can accurately identify patients at risk of developing pancreatic cancer, offering new hope for early detection and improved treatment. The study uses a combination of blood and fluid analysis to distinguish between low- and high-risk patients.
Amplified Sciences has received CLIA certification for its PanCystPro test, which helps risk stratify patients with pancreatic cystic lesions. The company plans to commercialize the test through an early access program and a clinical utility trial in 2025.
Researchers discovered that pancreatic cancer reprograms nerve cells to promote tumor growth. Blocking nerve function inhibited cancer growth and increased sensitivity to certain therapies.
Researchers at Oregon Health & Science University have developed a new blood test called PAC-MANN, which can detect pancreatic cancer with 85% accuracy. The test uses a small blood sample to identify changes in protease activity, a key indicator of the most common and deadly form of pancreatic cancer.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
Researchers at UCSF describe how to curb MYC levels by disrupting the protein assembly line controlled by RBM42. Disrupting RBM42 in pancreatic cancer cells stopped them from growing, suggesting drugs could be developed to do the same for other fast-growing cancers.
Researchers at UCSF used CRISPR gene editing technology to transform ordinary white fat cells into 'beige' fat cells that voraciously consume calories to make heat. Implanted near tumors, these cells outcompeted cancer cells for nutrients, beating back five types of cancer in lab experiments.
A novel approach transforms treatment for pancreatic cancer by repurposing WR-2721 to protect healthy tissue from radiation damage. Phase 1 and 2 clinical trials are underway to evaluate the safety and efficacy of the new therapy, which could add years of survival to patients.
A new approach to cancer therapy is being developed by inhibiting mechanotransduction, a process that regulates processes such as tumour progression and wound healing. The INTROPY project aims to validate the potential of six molecules in blocking this process, offering a new strategy for cancer treatment.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
The FDA has revoked authorization for the use of Red Dye 3 in food and ingested drugs, citing studies linking it to cancer in laboratory male rats. This decision is an important step forward in addressing modifiable risk factors that have the potential to reduce cancer risk.
A research team at Memorial Sloan Kettering Cancer Center has identified a novel molecular pathway leading to the formation of tertiary lymphoid structures (TLSs) in tumors. TLSs are immune cell clusters that can boost the local immune response and may be harnessed for immunotherapy treatments.
A recent study published in Cancer Letters reveals that the experimental test correctly identified 71% of pancreatic cancer samples compared to 44% by current gold-standard test. The new test detects two sugars produced by pancreatic cancer cells, reducing false negatives while maintaining low false positives.
Researchers have developed a way to detect circulating tumor cells in the bloodstream using biolasers, which can provide valuable information about the DNA organization inside cancer cells. The technique has been successfully tested on pancreatic and lung cancer patients, showing high accuracy rates of up to 99%.
Researchers at University of California San Diego have identified MICAL2 enzyme as a promising target for pancreatic cancer treatment. The study found that excessive production of the enzyme promotes tumor growth and spread in pancreatic ductal adenocarcinomas.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
A new study detects pre-malignant pancreatic lesions using Diffusion Tensor Imaging (DTI), a form of MRI, which could enable early diagnosis and effective therapies. The detection was successful in both transgenic mice and human samples, opening the way to non-invasive diagnostic tools for PanINs.
Researchers developed a deep learning model that classifies pancreatic cancer into molecular subtypes using histopathology images, achieving high accuracy and rapid turnaround time. The AI tool has the potential to improve patient outcomes by enabling timely and tailored treatment strategies.
Researchers at TUM have grown tumor organoids that reproduce the morphological complexity of pancreatic cancer cells in the laboratory. The team used machine learning to categorize the organoids into different phenotypes based on their appearance and behavior, which react differently to treatments.
A pioneering study of 192 Brazilian patients with pancreatic ductal adenocarcinoma identified genetic variants associated with the disease. The researchers found that 6.25% had pathogenic germline variants in genes predisposing to pancreatic cancer, and 13% had variants in genes associated with limited or previously unknown associations.
Dr. Direna Alonso-Curbelo's ERC Consolidator Grant project, IGNITE, aims to unravel the complex interplay between genetic and non-genetic factors that ignite tumor development. The research focuses on understanding how inflammation drives pancreatic cancer initiation and progression.
The American College of Surgeons' annual cancer report reveals that breast, bladder, and pancreatic cancers are increasingly treated with personalized therapies before surgery. Cancer stage at diagnosis remains a significant factor in determining patient survival rates.
Min Li will receive the 2024 Palade Prize for his contributions to pancreatology, recognizing his pioneering work on pancreatic cancer and metabolic reprogramming. He has been continuously funded by the National Cancer Institute for 15 years and has published over 200 high-impact articles.
MSK researchers have identified a compound that selectively kills glioblastoma cells while sparing healthy cells. They also developed a new method to study cancer evolution by introducing mutations in specific genes, allowing for the rapid regression of leukemia and understanding its behavior.
A randomized phase 2 clinical trial shows that adding high-dose, intravenous vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months. Patients also experience improved quality of life with reduced side effects.
An analysis of pancreatic cancer data found an increasing incidence among young adults, but stable mortality rates, suggesting detection of previously undetected disease. The study highlights the need for caution against overdiagnosis and high-risk surgery.
Researchers at UC Riverside develop a novel method to degrade the Pin1 protein, which is involved in pancreatic cancer development. The 'molecular crowbar' strategy has the potential to target and break down harmful proteins, offering new hope for cancer therapy.
Recent advancements in diagnostic techniques, including artificial intelligence integration, biomarker discoveries, and imaging technologies, have transformed the detection of pancreatic cancer. Key findings include improved sensitivity and accuracy of early-stage lesion identification using AI models, as well as the discovery of novel...
The National Comprehensive Cancer Network has updated its guidelines for genetic/familial high-risk assessment, incorporating the latest scientific research and expert recommendations to enhance screening practices and treatment options. The expanded guidelines cover various cancer types and provide guidance on genetic testing, heredit...
Researchers document remarkable response to pembrolizumab in patient with metastatic adenosquamous pancreatic cancer (ASCP) and KRAS G12C mutation. The study highlights potential shift in treatment of ASCP, a rare form of pancreatic cancer traditionally underserved by current therapies.
Researchers discovered that INPP4B drives the movement of lysosomes to the periphery of pancreatic cancer cells, releasing their contents into the extracellular space and disrupting the structural support network. This process enables the cells to migrate and invade other tissues, making it easier for the cancer to spread.
A new survey by Ohio State University shows that most people believe pancreatic disease affects only the elderly and that there is nothing they can do to reduce their risk. However, obesity increases lifetime risk for pancreatic cancer by 20%.
Researchers at the Hebrew University of Jerusalem have developed a highly selective inhibitor for Matrix Metallopeptidase 7 (MMP7), an enzyme crucial for cancer spread and progression. The novel peptide D'20 demonstrates remarkable stability and selectivity, targeting MMP7 while leaving similar enzymes unaffected.
A systematic review and meta-analysis found that weight-loss surgery reduces pancreatic cancer risk among individuals with obesity by 44%, and among those with both obesity and type 2 diabetes by 79%. The study suggests that metabolic-bariatric surgery may play a crucial role in reducing the risk of pancreatic cancer.
A new experimental blood test, combining CA199.STRA and CA19-9 biomarkers, improves accurate detection of pancreatic cancer in a lab setting by 27%, according to a recent study published in Cancer Letters. The test's effectiveness in a clinical lab setting is crucial for approval as a potential diagnostic method.
A multicenter study found that specific KRAS mutations in pancreatic cancer can affect patient outcomes, with some variants associated with better overall survival. The research suggests revising clinical guidelines to recommend routine molecular testing in all patients with pancreatic cancer.
Researchers at WVU are working on a project to inhibit the myeloperoxidase enzyme, which feeds pancreatic cancer growth. By targeting this enzyme, they hope to boost the body's immune system to fight cancer, showing promise in mouse models and potential for future clinical trials.
A new AI model generates detailed images of cancer tissue that imitate what its staining would look like, reducing the need for resource-intensive lab analyses. The VirtualMultiplexer uses contrastive unpaired translation to create accurate virtual pictures of diagnostic tissue colorations.
A new study by Cedars-Sinai Cancer investigators found that most patients with stage 1 and stage 2 pancreatic cancer are upstaged after surgery. Lymph node involvement is often missed in the staging process, leading to inaccurate diagnoses and poorer survival rates.
Researchers found that omitting the bolus-specific 5-fluorouracil (5-FU) portion from common chemotherapy regimens improves tolerability without sacrificing treatment effectiveness. The study of 11,765 patients shows no decrease in overall survival but a notable reduction in cytopenias.
The study used spatial transcriptomics and machine learning to analyze gene expression and cell distribution in PanINs, identifying key features of pancreatic cancer progression. Key findings include increased cell proliferation and decreased inflammatory signaling in high-grade PanIN lesions.
Researchers have developed a novel nanoparticle drug-delivery system to activate an immune pathway in combination with tumor-targeting agents, showing promising results in treating pancreatic cancer. Eight out of nine mice tested experienced tumor improvements, including two complete responses.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers have discovered a new approach to treating pancreatic ductal adenocarcinoma (PDAC), a rare type of pancreatic cancer. Folinic acid has been found to weaken the cancer's defenses by elevating levels of anti-cancer immune molecules, enabling a more effective immune response and slower tumor growth.
Researchers from Osaka University have developed a humanized antibody that blocks the DKK1–CKAP4 pathway, stimulating cancer cell growth. The new anti-CKAP4 antibody suppressed tumor formation in mice with both human and mouse tumors, as well as modulating anti-tumor immune reactions.
The study analyzes six major digestive system cancers worldwide and in China, revealing correlations between country HDI and cancer prevalence. Colorectal cancer is the most prevalent, while Asia accounts for 60.5% of new gastrointestinal cancer cases globally.
Scientists discovered a way to kill pancreatic cancer in mice by combining a ketogenic diet with an existing cancer drug. The diet blocks the cancer's only source of fuel, allowing the drug to take effect and shrink tumors. This finding opens a new vulnerability for treating cancer with diet and personalized therapies.
A new method for detecting pancreatic cancer has been introduced using glycopeptide probes that selectively detect specific antibodies in blood samples. These probes mimic tumor-associated antigens and show promise for early detection screenings.
Researchers identified a potential antigen for TCR recognition in melanoma, suggesting that RNLS protein could be recognized by T cells leading to local immune responses against the cancer. The study found that chemical complementarity between melanoma-resident TCR CDR3s and renalase-1 protein correlates with increased melanoma survival.